Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers

Running, not enrolling · Phase 1

Conditions studied: Healthy Volunteers

In brief

The objective of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of emraclidine following single oral administration of different immediate-release (IR) tablet formulations in healthy adult participants.

Key facts

Study ID

NCT07587008

Run by

AbbVie

People needed

12

Starts

2026-05-12

Expected to finish

2026-07-01

Last updated by the study team

2026-07-13

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body mass index of 18.5 to 32.0 kg/m2, inclusive.
• Total body weight >= 50 kg.

You may not qualify if…

• History of suicidal ideation within one year prior to study treatment administration and/or history of suicidal behavior or non-suicidal self-injury within two years prior to study treatment administration as evidenced by any "yes" answer to questions on the Columbia-Suicide Severity Rating Scale (C-SSRS) at the screening visit or upon initial confinement.
• Vital sign measurements, at Screening and Check-in:
• Systolic blood pressure >= 140 mmHg or < 100 mmHg
• Diastolic blood pressure >= 90 mmHg or < 60 mmHg
• Heart rate > 100 bpm or < 50 bpm
• Orthostatic hypotension, defined as a decrease of >= 20 mmHg in systolic blood pressure upon standing compared with the supine/sitting blood pressure measurement.
• Female participants of childbearing potential

Where it is running

• Acpru /Id# 283349 — Grayslake, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.